Image: The MRidium 3860+ infusion pump system allows patients to undergo MRI procedures (Photo courtesy of Iradimed).
A novel infusion pump compatible with magnetic resonance imaging (MRI) devices enables patients dependent on intravenous (IV) medication to undergo scanning.
The MRidium 3860+ infusion pump system is designed to provide a seamless approach that enables accurate, safe, and dependable IV medication and fluid delivery before, during, and after an MRI scan. A broad range of infusion rates support differing patient needs, including low levels for sedating children and infants in order to immobilize them during an MRI scan, mid-levels for continued IV infusion of medications to critically-ill patients, and high levels in the event of emergency situations.
The system incorporates a non-magnetic motor with a broad range of fluid flow control--from 0.1 to 1,400 mL per hour in order--to ensure the safe and predictable delivery of IV fluids during the MRI procedure. The IV infusion pump system also includes a proprietary single-use IV tubing sets, a non-magnetic pole, and a lithium battery, allowing it to be operated dependably in the presence of 0.2T to 3T magnets, up to a fully operational 10,000 gauss-line. Optional upgrades include a remote control, a sidecar, and an oxygen saturation pulse oximetry (SpO2) monitor.
The device also includes dose error reduction system (DERS) software, which enables users to create a unique drug library and establish nominal values and limits for dose and concentration for specified infusion protocols. With DERS, patient safety and user convenience are supported by user-programmed infusion hard (maximum and minimum) and soft (user confirmed) limits. The MRidium 3860+ infusion pump system is a product Iradimed (Winter Springs, FL, USA), and has been approved by the U.S. Food and Drug Administration (FDA).
“We have demonstrated that our IV pump and development processes meet the high standards established by FDA,” said Roger Susi, President and Chief Executive Officer of the Company. “With this clearance behind us, we are now able to allocate our full resources to finalizing the development of our MRI compatible patient vital signs monitoring system, and continue planning for its successful launch.”